Presentation Abstract: Time Course of Reduction in Itch Intensity During and Following Treatment with Nalbuphine ER Tablets: A Randomized, Placebo-Controlled Trial in Patients with Uremic Pruritus

New Haven, CT, November 16, 2016 – Trevi Therapeutics, Inc. (“Trevi”), a late-stage clinical development company developing Nalbuphine®ER for chronic pruritus conditions, will make an oral abstract presentation on their Phase 2/3 clinical trial of Nalbuphine HCI ER tablets at the American Society of Nephrology's Kidney Week 2016, in Chicago, IL on November 18th at 6:06 pm CST during the Patient-Centered Outcomes with Maintenance Dialysis Oral Abstract Session in Room W185.

The presentation FR-OR083: “Time Course of Reduction in Itch Intensity During and Following Treatment with Nalbuphine ER Tablets: A Randomized, Placebo-Controlled Trial in Patients with Uremic Pruritus” will be presented by Dr. Thomas Sciascia, the Company’s Chief Medical Officer.

Thomas Sciascia, MD, Trevi’s co-founder and Chief Medical Officer, said, “Uremic pruritus is a debilitating chronic condition which significantly affects quality of life. Despite the fact that 60% of dialysis patients suffer from pruritus, there are currently no approved treatments in the US or Europe. We were very pleased with the statistically significant outcome of reduction in itch intensity with Nalbuphine ER in this trial, as well as the other important findings in the study results that are clinically relevant to the serious medical condition of uremic pruritus”

About Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc. is a late-stage clinical development company focused on developing Nalbuphine ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic and neuropathic conditions. The Company is pursuing two conditions for clinical development: uremic pruritus and prurigo nodularis. Uremic pruritus is a persistent and debilitating itch in patients on dialysis that has been associated with increased mortality. Prurigo nodularis is a chronic pruritic dermatologic condition characterized by the presence of nodules on the skin. There are no approved therapies in the U.S. or EU for either condition.  The Company has completed Phase 2 trials in both of these conditions and has reported positive data.

Nalbuphine ER is an oral extended release opioid with a dual mechanism of action, mu receptor antagonist and kappa receptor agonist, both of which have been shown in research to be effective in abolishing itch. Because of Nalbuphine ER’s unique dual mechanism of action, which has shown efficacy in addressing pruritus in both animal studies and human clinical trials, the Company believes it can have broad utility in treating chronic pruritus.

Founded in 2011, Trevi is headquartered in New Haven, CT.

For additional information, visit www.trevitherapeutics.com.